Foundation for the Accreditation of Hematopoietic Cell Therapy (FAHCT) response to FDA (Docket No. 97N-0068)

E. J. Shpall; R. E. Champlin; A. C. Eaves; A. P. Gee; N. Collins; C. F. LeMaistre; R. O'Reilly; S. D. Rowley; K. Sullivan; W. P. Vaughan; P. L. Warkentin

doi:10.1089/scd.1.1997.6.287

Foundation for the Accreditation of Hematopoietic Cell Therapy (FAHCT) response to FDA (Docket No. 97N-0068)

E. J. Shpall, R. E. Champlin, A. C. Eaves, A. P. Gee, N. Collins, C. F. LeMaistre, R. O'Reilly, S. D. Rowley, K. Sullivan, W. P. Vaughan, P. L. Warkentin

Research output: Contribution to journal › Short survey › peer-review

Abstract

We believe the proposed model is appropriate to our current state of knowledge and recognize that FDA regulations will evolve as the field evolves. We thank you for the opportunity to work with FDA as its regulatory strategy is developed in the near future.

Original language	English (US)
Pages (from-to)	287-289
Number of pages	3
Journal	Journal of Hematotherapy
Volume	6
Issue number	4
DOIs	https://doi.org/10.1089/scd.1.1997.6.287
State	Published - 1997
Externally published	Yes

ASJC Scopus subject areas

Immunology
Hematology

Access to Document

10.1089/scd.1.1997.6.287

Cite this

@article{87dafe8032104607b49a7bdcfc60d409,

title = "Foundation for the Accreditation of Hematopoietic Cell Therapy (FAHCT) response to FDA (Docket No. 97N-0068)",

abstract = "We believe the proposed model is appropriate to our current state of knowledge and recognize that FDA regulations will evolve as the field evolves. We thank you for the opportunity to work with FDA as its regulatory strategy is developed in the near future.",

author = "Shpall, {E. J.} and Champlin, {R. E.} and Eaves, {A. C.} and Gee, {A. P.} and N. Collins and LeMaistre, {C. F.} and R. O'Reilly and Rowley, {S. D.} and K. Sullivan and Vaughan, {W. P.} and Warkentin, {P. L.}",

year = "1997",

doi = "10.1089/scd.1.1997.6.287",

language = "English (US)",

volume = "6",

pages = "287--289",

journal = "Journal of Hematotherapy",

issn = "1061-6128",

publisher = "Mary Ann Liebert Inc.",

number = "4",

}

TY - JOUR

T1 - Foundation for the Accreditation of Hematopoietic Cell Therapy (FAHCT) response to FDA (Docket No. 97N-0068)

AU - Shpall, E. J.

AU - Champlin, R. E.

AU - Eaves, A. C.

AU - Gee, A. P.

AU - Collins, N.

AU - LeMaistre, C. F.

AU - O'Reilly, R.

AU - Rowley, S. D.

AU - Sullivan, K.

AU - Vaughan, W. P.

AU - Warkentin, P. L.

PY - 1997

Y1 - 1997

N2 - We believe the proposed model is appropriate to our current state of knowledge and recognize that FDA regulations will evolve as the field evolves. We thank you for the opportunity to work with FDA as its regulatory strategy is developed in the near future.

AB - We believe the proposed model is appropriate to our current state of knowledge and recognize that FDA regulations will evolve as the field evolves. We thank you for the opportunity to work with FDA as its regulatory strategy is developed in the near future.

UR - http://www.scopus.com/inward/record.url?scp=0030800526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030800526&partnerID=8YFLogxK

U2 - 10.1089/scd.1.1997.6.287

DO - 10.1089/scd.1.1997.6.287

M3 - Short survey

C2 - 9377066

AN - SCOPUS:0030800526

SN - 1061-6128

VL - 6

SP - 287

EP - 289

JO - Journal of Hematotherapy

JF - Journal of Hematotherapy

IS - 4

ER -

Foundation for the Accreditation of Hematopoietic Cell Therapy (FAHCT) response to FDA (Docket No. 97N-0068)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this